Fundraising Fox
Harwell · Seed–Series A · 4 people tracked
Find your way into Longwall Venture Partners LLP
Sign up to see every warm intro you have to Longwall Venture Partners LLP
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Longwall Venture Partners LLP team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Longwall Venture Partners provides early-stage venture capital and company-building support for UK deeptech, helping turn scientific research into enduring global businesses. The firm emphasizes patient capital and technical fluency, recognizing that deep, emergent technology requires investors who understand the long journey from prototype to product and from first customer to category leader. Longwall works closely and deliberately with founders from day one, prioritizing customer engagement and avoiding over-engineering. Active since 2008, it positions itself as a long-term partner willing to back ambitious hard-science ideas that other investors underestimate.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from the firm's website & public directories
Founder mafia
2 people who came through Longwall Venture Partners LLP went on to found or lead other companies.
What they invest in
from 13 of 17 portfolio companiesDeep Tech ×10Biotech ×7Hardware ×6Healthtech ×5Cleantech ×3Medical Devices ×3Advanced Manufacturing ×2Climate Tech ×2
HQs:United Kingdom×7
Investments · 17 tracked
founders shown can be your intro pathBiofidelity develops decentralized biomarker testing solutions, starting with Aspyre Lung Reagents for analyzing DNA and RNA variants in lung cancer research.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Barnaby Balmforth, PhDJonathan Senior, MD
Co-investorsOctopus VenturesPerscitus LLP
University of Oxford spinout whose imaging technology aids diagnosis and treatment of cardiovascular disease.
Co-investorsBusiness Growth FundCreative Destruction Lab (CDL)Oxford Investment Consultants LLPOxford Science Enterprises
Keit is a technology hardware company founded in 2013 as a spin-out from the Science and Technology Facilities Council and European Space Agency Business Incubation Centre, developing new technology for established industries.
Advanced ManufacturingDeep TechHardwareOxfordshire, GB
Co-investorsUK Innovation & Science Seed FundWren CapitalFuture Planet Capital
Kinomica develops mass spectrometry-based diagnostic tests that measure protein activity to predict patient responses to multiple drugs.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesMacclesfield, GB
LettUs Grow develops aeroponic irrigation systems and technologies for controlled environment agriculture, enabling growers to produce fresh food with reduced waste and carbon footprint.
AgTechCleantechClimate TechFoodTechHardwareBristol, GB
Co-investorsBlue Horizon Corporation
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalIllumina VenturesM VenturesOMX VenturesARCH Venture Partners
MFX develops the Cyto Engine, an automated bioprocessing platform that accelerates development and manufacturing of engineered cells for cell and gene therapy.
BiotechDeep TechHealthtech
Co-investorsCambridge Angels group
Mirico provides an automated digital platform for continuous methane emissions measurement and monitoring at industrial sites, delivering real-time data for regulatory reporting and operational optimization.
CleantechClimate TechDeep TechEnergyHardwareIoT
Damien Weidmann(Chief Scientific Officer)
Co-investorsFuture Planet CapitalOxford Investment Opportunity Network (OION)Foresight GroupNew Climate Ventures
OrganOx develops the metra platform, a device that extends organ preservation time for liver transplants by maintaining continuous perfusion with oxygenated blood-based solutions, enabling surgeons to better assess organ viability and make more informed transplant decisions.
BiotechHealthtechMedical DevicesOxford, GB
Prof. Peter Friend(Co-Founder)
Co-investorsAmadeus Capital PartnersAnjostBusiness Growth FundHealthQuest CapitalIntuitive VenturesLauxera Capital Partners+2 more
Oxford Space Systems designs and manufactures deployable antennas for satellites, focused on reducing mass and improving stowage efficiency and performance.
Deep TechHardwareSpace TechHarwell, GB
Co-investorsCambridge Angels groupEMV CapitalForesight GroupFuture Planet CapitalMartlet CapitalOxford Investment Opportunity Network+5 more
Oxford PV develops perovskite-on-silicon tandem solar cell technology aimed at increasing the efficiency of photovoltaic modules.
CleantechEnergyNew Materials
Henry Snaith(Founder)
Co-investorsPerivoli Innovations
OxSonics is a clinical-stage therapeutics company developing a platform technology intended to improve the delivery and penetration of anti-cancer drugs into solid tumours.
BiotechDeep TechHealthtech
Co-investorsAnjostPerivoli Innovations
Verdel Instruments develops total correlation mass spectrometry (TOC-MS), a method using stored waveform ion radius modulation (SWIM) to generate MS/MS data for every analyte in a complex mixture.
BiotechDeep TechHardware
Wayland Additive develops electron beam additive manufacturing technology for metal production, leveraging decades of expertise from the semiconductor industry.
Advanced ManufacturingDeep TechHardwareNew Materials
Will Richardsonin
Co-investorsInnovate UK
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Focus SensorsLettUs GrowOxfordbio
Portfolio news
latest coverage across their companiesLightcast · finsmes.com · Apr 15, 2026
OrganOx · eu-startups.com · Aug 25, 2025
Principals & officers · per Companies House
what is this? ⓘLLP designated member · since 2017
LLP designated member · since 2011
LLP designated member · since 2011
David James Edmonds Denny — 25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership
Matthew Gerard Winston Frohn — 25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership
Jane Elizabeth Burgoyne — 25–50% of voting rights, right to share surplus assets 25 to 50 percent limited liability partnership
Frequently asked questions
- How many investments has Longwall Venture Partners LLP made?
- Longwall Venture Partners LLP has 17 tracked investments.
- What stage does Longwall Venture Partners LLP invest at?
- Longwall Venture Partners LLP invests at the Seed, Series A stages.
- What is Longwall Venture Partners LLP's typical check size?
- Longwall Venture Partners LLP typically writes checks of $2M.
- What sectors does Longwall Venture Partners LLP focus on?
- Longwall Venture Partners LLP focuses on Biotech, Deep Tech, Hardware, Healthtech, IoT, Medical Devices, New Materials, SaaS.
- Where is Longwall Venture Partners LLP located?
- Longwall Venture Partners LLP is headquartered in Harwell, GB.
- Does Longwall Venture Partners LLP lead rounds?
- Yes, Longwall Venture Partners LLP leads investment rounds.
- Who does Longwall Venture Partners LLP co-invest with?
- Longwall Venture Partners LLP most often shares deals with Perivoli Innovations, Anjost, Business Growth Fund, among 27 tracked co-investors.
Similar investors
The Alibaba Entrepreneurs Fund is a not-for-profit initiative of Alibaba Group that provides investment capital and strategic guidance to entrepreneurs and young people, focusing on Hong Kong and Taiwan-nexus startups.
Karista is an early-stage European venture capital firm founded in 2001 that invests in Health, DeepTech (Space & Defense) and Digital companies, typically leading rounds from Seed to Series B+.
Martlet Capital is an early-stage investor based in Cambridge, UK, providing patient capital to deep tech and life sciences B2B startups. Its operational VC business is owned and portfolio-managed by EMV Capital.
Qbic is an inter-university venture capital fund that backs the transformation of technological breakthroughs from its academic and research partners into sustainable businesses.
Vespucci Partners is a venture capital firm that emphasizes sustainability and ESG principles across its portfolio, seeking startups and investments aligned with responsible, environmentally and socially conscious business practices.